Delay of active antimicrobial therapy in haematological patients with Gram-negative bacilli bacteraemia during profound neutropenia exposes them to increased morbidity and mortality.
INTRODUCTION
Bloodstream infections (BSI) caused by enterobacteria (EB-BSI) are a major cause of morbidity and mortality in haematological patients experiencing profound neutropenia (Pizzo et al., 1982) . In these patients, prompt initiation of empirical treatment with antibacterial agents that are active against the offending bacteria at the onset of fever is mandatory and must be continued as long as the neutropenia lasts (Micol et al., 2014) . Indeed, it has been evidenced that any delay in the initiation of appropriate active antimicrobial therapy significantly and independently jeopardizes the outcome of patients with neutropenia (Tumbarello et al., 2008; Ortega et al., 2009; Gudiol et al., 2010; Cornejo-Juárez et al., 2012) . Recent recommendations from the European Organization for Research and Treatment of Cancer (EORTC) (Averbuch et al., 2013) and the Infectious Diseases Society of America (IDSA) (Freifeld et al., 2011) for initial empirical treatment of patients with uncomplicated febrile neutropenia both include broad-spectrum beta-lactam (BSBL) antibiotics, including piperacillin/tazobactam, ceftazidime or cefepime. Treatment with carbapenems should be reserved for patients with risk factors for infection with resistant micro-organisms, i.e. previous infection or colonization by such micro-organisms, a hospital stay with a high rate of endemicity or for seriously ill patients (Averbuch et al., 2013) . However, the recent rise in the prevalence of broadspectrum beta-lactam resistant enterobacteria (BSBL-RE) strains, which is largely the consequence of the spread of the CTX-M-type extended-spectrum beta-lactamase (ESBL) enzyme-producing strains in the community as well as in hospitals, makes it increasingly difficult to presumptively identify patients with risk factors for colonization (Tumbarello et al., 2011) . This situation may lead to an excessive use of carbapenems, which are currently the last line of beta-lactam antibiotics available against systemic infections caused by ESBL-or high level AmpC type cephalosporinase-producing enterobacteria. The digestive tract is the reservoir of enterobacteria in humans. In patients experiencing profound neutropenia, translocation of strains originating from the predominant intestinal population of enterobacteria is the main cause of EB-BSI (Tancrède & Andremont, 1985) . Therefore, patients undergoing intensive cytotoxic chemotherapy in the haematology ward of our hospital undergo a weekly test for the BSBL-RE intestinal population with a semiquantitative evaluation of bacterial levels. Local recommendations for first-line empirical therapy in these patients include a combination of piperacillin/tazobactam or cefepime in non-carriers, whereas imipenem/cilastatin treatment is recommended for patients having experienced previous intestinal colonization or infection with BSBL-RE isolates and those with septic shock. The aims of our study were to determine the predictive values of testing patients for BSBL-RE carriage in forecasting the susceptibility to BSBLs of the bacterial strains responsible for EB-BSI and the impact of semiquantitative assessment of BSBL-RE carriage levels on the performances of the test. The antibiotic management of febrile episodes in relation with the carriage status of patients was also evaluated.
METHODS
Patients. This retrospective study spanning 2002 to 2011 concerned high-risk neutropenic patients who had developed EB-BSI during their stay in the laminar airflow rooms of the haematological ward at the Gustave Roussy Institute, a 400-bed comprehensive anticancer centre. The patient population included subjects with acute leukaemia who had received intensive chemotherapy and those who had received haematopoietic stem cell transplantation for any haematological malignancy and had developed EB-BSI during profound neutropenia (white blood cells v500 mm 23 ). Only cases of bacteraemia with a probable intestinal origin were studied. Thus, patients who had developed EB-BSI with an identified clinical portal of entry (e.g. catheter-related infection or urinary tract infection) were excluded. Because intestinal colonization may change over time, patients who had no stool sample obtained during the 7 days before the onset of the EB-BSI episode were also excluded. Only the first EB-BSI episode was considered when several occurred in a same included patient. No prophylactic antibiotherapy against bacterial infections had been administered in the ward during the study period.
All positive blood cultures with enterobacteria in haematological patients were extracted from the laboratory electronic database. Clinical charts and microbiological data were reviewed for all EB-BSI. Demographic and medical data, including the underlying haematological disease, chemotherapy protocol, treatment phase, white blood cell counts, antimicrobial therapy administered before and at the onset of EB-BSI, and death during the related neutropenic episode were collected.
Microbiological methods. Blood cultures had been drawn from patients with neutropenia at the onset of fever (w38u) and at least daily if the fever persisted. Five to ten millilitres of blood drawn from the central venous catheter and/or from a direct venipuncture were inoculated both in aerobic and anaerobic blood culture bottles with charcoal (Bact/ALERT system, bioMérieux). Blood culture bottles were then incubated and checked for microbial growth for 5 days, as recommended by the manufacturer. When positive, a direct smear examination and antibiotic susceptibility testing by an agar diffusion assay were performed directly from blood culture broth. At least one weekly stool culture had been performed to assess patient intestinal colonization with aerotolerant Gram-negative bacilli, including BSBL-RE. Briefly, all stool samples collected in this study were diluted 1/ 1000 in saline and 100 ml of the faecal suspensions were plated on Drigalski agar alone and supplemented with 2 mg ceftazidime l 21 until 2007 and thereafter on a biplate containing two selective media: MacConkey agar supplemented with 2 mg ceftazidime l 21 and Drigalski agar supplemented with 1.5 mg cefotaxime l 21 (bioMérieux). The level of BSBL-RE intestinal carriage was quoted respectively as (0), (+), (++) or (+++) when 0, 1 to 9, 10 to 99 or 100 and more colonies were grown on the plates. All different-looking colonies were analysed for antibiotic susceptibility by agar diffusion assay. ESBL production was assessed by the double-disc synergy test according to the recommendations of the French Microbiology Society (http://www.sfm-microbiologie.org). High-level cephalosporinase production was characterized by testing the ability of cloxacillin to restore the activity of third-generation cephalosporins on MuellerHinton agar medium supplemented with 200 mg cloxacillin l 21 (bioMérieux). Species were identified with the VITEK2 system (bioMérieux). Species and strain susceptibility patterns were compared when BSBL-RE were isolated from blood and faecal samples in the same patient. All microbiological results were made available to clinicians during the study period. Preliminary results of patient screening for BSBL-RE carriage were obtained the next day of stool sampling in most of the cases.
Statistical methods. Analyses were performed using the R software (version 2.13.0, http://www.cran.r-project.org). Univariate analyses of discrete variables were performed using the two-sided Pearson chisquared test and Fisher exact test; the Student t-test and Wilcoxon's test were used to test continuous variables. All tests performed were two-sided and the level of significance was set at 5%. All variables with univariate P values below 0.20 were included in the multivariate analysis, which was performed using descending stepwise logistic regression. The final logistic models were tested for statistical stability using the RVAideMemoire package (http://cran.r-project.org/web/ packages/RVAideMemoire/).
RESULTS

Patient characteristics
A total of 313 patients with at least one blood culture grown with enterobacteria were identified retrospectively in the electronic database of the laboratory. Among these patients, 169 were excluded because they failed to fulfil the inclusion diagnostic criteria. After the exclusion of 40 other patients with no stool culture performed during the 7 days prior to the EB-BSI, 104 patients with EB-BSI were selected for the final analysis (Table 1) . The white blood cell count was 0.248|10 9 l 21 and the median duration of neutropenia was 4.5 days at the onset of EB-BSI. Assessment of antibiotic exposure revealed that 30 of the 104 patients (29%) had received BSBLs during the hospital stay before the onset of EB-BSI. Among them, eight (27%) patients had received another category of antibiotic drug: fluoroquinolones (three cases), aminoglycosides (two cases), colistin (two cases) or vancomycin (one case).
Microbiological data
The median time that had elapsed between stool sampling and the EB-BSI was 2 days (range 0-7 days). Stool cultures from the 104 bacteraemic patients grew with enterobacteria. Quantification of the total population of enterobacteria showed a medium or a high [(++) or (+++)] level in 96 (92%) patients while low or no detectable levels [(+) or (0)] were found in the eight other patients (Table 1 ). Stool samples from 16 patients (15.4%) grew with 17 BSBL-RE isolates. ESBL detection was positive for 10 strains, while the seven other isolates displayed a high-level cephalosporinase production phenotype (Table  2) . When detected, the amount of BSBL-RE was low (+) or medium (++) in seven samples and high (+++) in the nine others (Table 3) . From the 104 positive blood cultures, three were positive with two different isolates, leading to a total of 107 bacterial isolates. The species identified from blood cultures was mainly Escherichia coli (Table 2) . BSBL-RE were isolated from blood cultures in 10 patients (10%). The ESBL test was positive in six cases, while the other four isolates displayed a high-level cephalosporinase production phenotype (Table 2 ). For eight of these 10 patients, a strain of the same species and with a similar susceptibility pattern had been isolated from the previous stool culture. In the two other patients, BSBL-RE intestinal carriage was not detected in the last stool culture preceding the bacteraemia. One of these patients had received cefepime plus ciprofloxacin at the time of stool sampling and no growth of any enterobacteria had been observed from the sample. The patient had, however, previously been identified as an ESBL-producing Enterobacter cloacae carrier. In the other case, BSBL-RE had not been detected in the stool sample collected 2 days before bacteraemia but only in those following the EB-BSI, suggesting that the patient had recently acquired the resistant strain.
Empirical antibiotherapy
At the time of the onset of EB-BSI, empirical antibiotic therapy had been initiated with piperacillin/tazobactam, ceftazidime or cefepime in 63 (61%) cases, whereas 41 (39%) had received imipenem/cilastatin. In 23 (22%) cases, empirical BSBL antibiotherapy had been administered combined with aminoglycosides (19 cases) or fluoroquinolones (4 cases). Except for a strain that was resistant to all beta-lactams including imipenem, the strains isolated from the other 103 EB-BSI were susceptible to the empirical BSBL administered at the onset of the febrile episodes.
Statistical analysis
The univariate analysis of features significantly associated with BSBL-RE carriage within the 104 patients with EB-BSI identified previous exposure to carbapenems (Pv0.001) and to non-beta-lactam antibiotics (P50.02), empirical treatment of EB-BSI with carbapenems (Pv0.001) and with antibiotic combination (P50.04), the presence of BSBL-RE (Pj0.001), ESBL-EB (P50.005), non-Escherichia coli EB (Pv0.001) in blood cultures and death during the related neutropenic episode (P50.05) ( Table 3 ], suggesting a relationship between the BSBL-RE carriage density and the risk of EB-BSI with a BSBL-RE strain. Sensitivity, specificity and positive and negative predictive values of BSBL-RE faecal detection for EB-BSI with BSBL-RE were 80%, 91%, 50% and 98%, respectively. However, when the group of patients with a high level of BSBL-RE was compared with those with either a medium or low level or no carriage of BSBL-RE, the positive predictive value rose to 67%.
DISCUSSION
Antibiotic policies in haematological wards are a particularly sensitive issue because (i) delayed active antimicrobial therapy significantly worsens patient outcome, (ii) BSBL-RE carriage rates and infection are on the increase worldwide both in the community setting and in hospitals and (iii) systematic recourse to carbapenems is discouraged by the current emergence of carbapenemase-producing enterobacteria (Friedman & Whitney, 2008; Cantó n et al., 2012; Walsh & Toleman, 2012) . In this context, attempts to identify markers that would enable clinicians to presumptively choose the most appropriate antibiotic treatment in neutropenic patients with bacteraemia are particularly relevant.
We found that in neutropenic patients exhibiting EB-BSI, BSBL-RE intestinal carriage was significantly associated with the isolation of BSBL-RE from blood cultures. ESBL , Fisher exact, Wilcoxon or Welch tests (a50.05). Odds ratios are given with their 95 % confidence interval. DAll variables with P,0.20 were included in multivariate descending stepwise logistic regression. Only odds ratios of the significant variables in the final multivariate model are given with their 95 % confidence interval. NS, not significant.
Faecal colonization and bacteraemia during neutropenia
intestinal carriage was also found to be associated with an increased risk of ESBL-producing enterobacteria bacteraemia in a recent study concerning a large cohort of haematological and oncological patients (Liss et al., 2012) . However, another previous study conducted in similar patients failed to show any association between faecal colonization by ESBL-producing Escherichia coli strains and an increased risk of infections with the same strain, probably due to a lack of power resulting from the scarcity of documented infections, as underlined by the authors (Arnan et al., 2011) . The present study was specifically designed to assess the predictive values of the test and was performed in a large and very homogeneous cohort of neutropenic haematological patients with EB-BSI. We showed that the assessment of BSBL-RE faecal detection yielded high specificity (91%) and a excellent negative predictive value (98%) in forecasting susceptibility to BSBL of enterobacterial strains causing bacteraemia. Thus, BSBL antibiotics can be confidently used in patients without recent detectable BSBL-RE faecal detection. Moreover, we observed a significant relationship between the level of BSBL-RE faecal detection and the risk of BSBL-RE BSI. Patients in whom a high level of BSBL-RE intestinal carriage is detected are prone to have a strain with the same pattern isolated from blood cultures and should, therefore, receive carbapenems as empirical antibiotic treatment. Because quantitative microbiological analysis of stool samples is very labour intensive and cannot be routinely performed in clinical laboratories, we have chosen to address the usefulness of a semiquantitative evaluation of faecal colonization for BSBL-RE intestinal carriage. Taken together, our results indicate that close monitoring of BSBL-RE intestinal carriage may be helpful in initiating the appropriate empirical antimicrobial treatment while reserving the use of carbapenems for BSBL-EB carriers, especially in haematological wards exhibiting high rates of bacteraemia caused by ESBL-EB (Kim et al., 2013; Kwon et al., 2013) .
In our hospital, physicians in the haematological wards are accustomed to taking into account the BSBL-RE intestinal carriage status of neutropenic patients, when available, before prescribing empirical antibiotic therapy for febrile episodes. The analysis of empirical treatment of the patient cohort showed that the imipenem/cilastatin combination was more frequently administered to patients with BSBL-RE carriage, whereas piperacillin/tazobactam or cefepime were predominantly used for non-carriers. Indeed, all the patients with BSBL-RE bacteraemia had received appropriate empirical treatment of febrile episodes, except for the patient who had been infected with a strain that was resistant to all beta-lactams, including carbapenems, as predicted by the results of the stool culture. However, 31% (27/88) of the non-carriers had been treated with imipenem/cilastatin, despite the local recommendations. This could be explained by the fact that some of them had already been exposed to piperacillin/tazobactam or cefepime during the on-going hospitalization and before the initiation of the empirical treatment of the bacteraemia.
Our study has, however, some limitations. First, it was based on a retrospective cohort, which may limit our conclusions. Then, since only the patients exhibiting documented bacteraemia were included, our results cannot be extended to neutropenic patients with febrile episodes of unknown origin, even though they represent a substantial proportion of antibiotic treatment indications in haematological wards (Bow, 2005) .
The prevalences of ESBL-and carbapenemase-producing enterobacteria are growing steadily worldwide although the rates vary somewhat from one country to another (Woerther et al., 2013) . At the same time, the renewal of drugs that are active against resistant Gram-negative bacilli is very limited and it is quite unlikely that this situation will change in the near future (Bow, 2013) . Our results suggest that monitoring patients' intestinal levels of colonization with BSBL-RE-and carbapenems-resistant Gram-negative bacilli may be helpful to guide the choice of antibiotic treatment of EB-BSI in neutropenic haematological patients. Further prospective studies are, however, needed to assess its impact on morbidity and mortality due to systemic Gram-negative bacilli infections in high-risk haematological patients and on antibiotic stewardship.
